Phio Pharmaceuticals Announces Closing of $7.7 Million Registered Direct Offering of Common Stock Priced At-the-Market

Feb 17, 2021 | Press Releases

MARLBOROUGH, Mass., Feb. 17, 2021 — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today...

Phio Pharmaceuticals Announces $7.7 Million Registered Direct Offering of Common Stock Priced At-the-Market

Feb 12, 2021 | Press Releases

MARLBOROUGH, Mass., Feb. 12, 2021 — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today...

Phio Pharmaceuticals Announces Closing of $14.0 Million Private Placement Priced At-the-Market

Jan 25, 2021 | Press Releases

MARLBOROUGH, Mass., Jan. 25, 2021 — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today...

Phio Pharmaceuticals Announces $14.0 Million Private Placement Priced At-the-Market

Jan 21, 2021 | Press Releases

MARLBOROUGH, Mass., Jan. 21, 2021 — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today...

Phio Pharmaceuticals to Participate in the H.C. Wainwright BioConnect 2021 Conference

Jan 4, 2021 | Press Releases

MARLBOROUGH, Mass., Jan. 4, 2021 — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today...

Phio Pharmaceuticals to Participate in the 3rd Annual Evercore ISI HealthCONx Conference

Nov 19, 2020 | Press Releases

MARLBOROUGH, Mass., Nov. 19, 2020 — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today...